FDA Approves The 1st Immunotherapy Medication For Breast Cancer

The U.S. Food and Drug Administration (FDA) has agreed on the first medication for breast cancer immunotherapy.

Swiss drug company Roche approved on Friday the drug Tecentriq for the treatment of Triple-Negative Breast Cancer, which represents About 15% of cases. Used with standard chemotherapy..

Dr. Amy Teerstein, a breast cancer specialist at Mount Sinai in New York, described it as a "tremendously exciting news."

Approved for two other cancers, Tecentriq works by enhancing the ability of the immune system to spot and kill cancer cells.

In a study conducted by 900 orders, the benefits were modest. Those who received Tecentriq in addition to chemotherapy went two months longer on average without deteriorating cancer compared to those on chemotherapy alone. The combo causes neuralgia, nausea and other side effects.

Mention that Tecentriq price about $13,400 per month

Source: AP